Vemurafenib in leptomeningeal carcinomatosis from melanoma: A case report of near-complete response and prolonged survival

Melanoma Research

Volumn 26, Issue 3, 2016, Pages 312-315

  Floudas, Charalampos S ^a   Chandra, Abhinav B ^a,b   Xu, Yiqing ^b  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b Maimonides Cancer Center   (United States)

Author keywords

melanoma; meningeal carcinomatosis; targeted therapy; vemurafenib

Indexed keywords

B RAF KINASE; CISPLATIN; DACARBAZINE; GADOLINIUM; GLUCOSE; SODIUM; VEMURAFENIB; VINBLASTINE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BRADYCARDIA; BRAIN RADIATION; BRAIN VENTRICLE PERITONEUM SHUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CASE REPORT; COMMUNICATING HYDROCEPHALUS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFUSION; CONTRAST ENHANCEMENT; DIARRHEA; DROWSINESS; DRUG DOSE REDUCTION; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; LETHARGY; LYMPHADENOPATHY; MENTAL HEALTH; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROIMAGING; PARIETAL LOBE; POSTERIOR FOSSA; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; STEREOTACTIC RADIOTHERAPY; STEREOTACTIC TREATMENT; SYSTEMIC THERAPY; TEMPORAL LOBE; TREATMENT RESPONSE; VOMITING; WEAKNESS; COMPLICATION; MELANOMA; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INDOLES; MELANOMA; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONAMIDES; SURVIVAL ANALYSIS;

EID: 84961226034     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000257     Document Type: Article

References (20)

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22:2865-2872.
2. Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol 2008; 10:1010-1018.
3. Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 2013; 4 (Suppl 4):S265-S288.
4. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
5. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012; 380:358-365.
6. Gorantla V, Kirkwood JM, Tawbi HA. Melanoma brain metastases: an unmet challenge in the era of active therapy. Curr Oncol Rep 2013; 15:483-491.
7. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004; 22:2101-2107.
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
9. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:782-789.
10. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013; 113:411-416.
11. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379:1893-1901.
12. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:1087-1095.
13. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, et al. Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014; 50:611-621.
14. Schäfer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkämper C, et al. Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol 2013; 31: e173-e174.
15. Wilgenhof S, Neyns B. Complete cytologic remission of V600E BRAF-mutant melanoma-associated leptomeningeal carcinomatosis upon treatment with dabrafenib. J Clin Oncol 2015; 33:e109-e111.
16. Kim DW, Barcena E, Mehta UN, Rohlfs ML, Kumar AJ, Penas-Prado M, Kim KB. Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. BMC Cancer 2015; 15:400.
17. Simeone E, de Maio E, Sandomenico F, Fulciniti F, Lastoria S, Aprea P, et al. Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep 2012; 6:131.
18. Lee JM, Mehta UN, Dsouza LH, Guadagnolo BA, Sanders DL, Kim KB. Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res 2013; 23:175-178.
19. Peuvrel L, Saint-Jean M, Quéreux G, Brocard A, Khammari A, Knol AC, Dréno B. Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib. J Neurooncol 2014; 120:147-154.
20. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 2012; 342:33-40.